drugset / Trial / NCT01295645

Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis

NCT01295645

Phase 2 Active not recruiting 27 enrolled M.D. Anderson Cancer Center
RandomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if adding cidofovir to the standard of care can improve symptoms of hemorrhagic cystitis caused by the BK virus as compared to standard of care alone. The safety of cidofovir will also be studied.

Timeline

Start
2011-03-17
Primary completion
2028-03-15
Completion
2028-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject CIDOFOVIR ANHYDROUS Small molecule 0.5 mg/kg Intravenous